US 12,133,966 B2
Methods, systems, and apparatus for administering an antibody treatment via infusion
Regina E. Herzlinger, Belmont, MA (US)
Filed by Regina E. Herzlinger, Belmont, MA (US)
Filed on Sep. 29, 2023, as Appl. No. 18/374,816.
Application 18/374,816 is a continuation of application No. PCT/US2023/021983, filed on May 12, 2023.
Application PCT/US2023/021983 is a continuation in part of application No. 17/840,423, filed on Jun. 14, 2022, granted, now 11,806,507.
Application 18/374,816 is a continuation in part of application No. 17/840,423, filed on Jun. 14, 2022, granted, now 11,806,507.
Application 17/840,423 is a continuation in part of application No. 17/558,295, filed on Dec. 21, 2021.
Claims priority of provisional application 63/457,898, filed on Apr. 7, 2023.
Claims priority of provisional application 63/343,963, filed on May 19, 2022.
Claims priority of provisional application 63/341,928, filed on May 13, 2022.
Claims priority of provisional application 63/286,353, filed on Dec. 6, 2021.
Claims priority of provisional application 63/280,953, filed on Nov. 18, 2021.
Claims priority of provisional application 63/253,790, filed on Oct. 8, 2021.
Claims priority of provisional application 63/249,299, filed on Sep. 28, 2021.
Claims priority of provisional application 63/227,803, filed on Jul. 30, 2021.
Claims priority of provisional application 63/223,921, filed on Jul. 20, 2021.
Claims priority of provisional application 63/220,854, filed on Jul. 12, 2021.
Claims priority of provisional application 63/129,401, filed on Dec. 22, 2020.
Prior Publication US 2024/0050646 A1, Feb. 15, 2024
Int. Cl. A61M 5/142 (2006.01)
CPC A61M 5/14232 (2013.01) 12 Claims
OG exemplary drawing
 
1. A kit comprising a volume of solution to be administered to a patient and an infusion device for administering the volume of solution to the patient by intravenous infusion,
wherein the volume of solution comprises one or more antibodies selected from the group consisting of: (i) one or more monoclonal and/or polyclonal antibodies (mAbs and/or pAbs), (ii) one or more antibody drug conjugates (ADCs), (iii) one or more lipid drug conjugates (LDCs), and (iv) intravenous immunoglobulin (IVIg);
wherein the infusion device comprises (a) a pump, and (b) a disposable infusion set comprising a tubing line or lines fluidly connecting an intravenous (IV) bag or other receptacle containing the volume of solution to the pump, and/or the pump to the patient, and
wherein the pump administers the volume of solution at a dosing rate of at least 35 mg of the one or more antibodies per minute and at a total antibody concentration of less than or equal to 20 mg/mL.